RSPO2-LGR5 signaling has tumour-suppressive activity in colorectal cancer

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wu, Changjie ^a   Qiu, Sunquan ^a   Lu, Liting ^a   Zou, Jiawei ^a   Li, Wen Feng ^b   Wang, Ouchen ^b   Zhao, Haina ^a   Wang, Hongxiao ^a   Tang, Jiajia ^a   Chen, Lin ^a   Xu, Tao ^a   Sun, Zhongsheng ^a,c   Liao, Wanqin ^a   Luo, Guangbin ^d   Lu, Xincheng ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5; LGR5 PROTEIN; PROTEIN; RECEPTOR; RSPO2 PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN; ZINC AND RING FINGER 3; G PROTEIN COUPLED RECEPTOR; LGR5 PROTEIN, HUMAN; R-SPONDIN2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

CANCER; GENE EXPRESSION; INHIBITION; PHYSIOLOGICAL RESPONSE; PROTEIN; SENSORY SYSTEM; TUMOR;

ADULT; ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INFILTRATION; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEEDBACK SYSTEM; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REDUCTION; SIGNAL TRANSDUCTION; SMOKING; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; WNT SIGNALING PATHWAY; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84903387739     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4149     Document Type: Article

References (52)

1. Jemal, A. et al. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Smith, G. et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc. Natl Acad. Sci. USA 99, 9433-9438 (2002).
3. MacDonald, B. T., Tamai, K. & He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26 (2009).
4. Fodde, R., Smits, R. & Clevers, H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67 (2001).
5. Muzny, D. M. et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
6. Yoon, J. K. & Lee, J. S. Cellular signaling and biological functions of R-spondins. Cell Signal. 24, 369-377 (2012).
7. de Lau, W. B., Snel, B. & Clevers, H. C. The R-spondin protein family. Genome Biol. 13, 242 (2012).
8. Kim, K. A. et al. R-Spondin proteins: a novel link to beta-catenin activation. Cell Cycle 5, 23-26 (2006).
9. Kim, K. A. et al. R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol. Biol. Cell 19, 2588-2596 (2008).
10. Carmon, K. S., Gong, X., Lin, Q., Thomas, A. & Liu, Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/{beta}-catenin signaling. Proc. Natl Acad. Sci. USA 108, 11452-11457 (2011).
11. de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293-297 (2011).
12. Glinka, A. et al. LGR4 and LGR5 are R-spondin receptors mediating Wnt/betacatenin and Wnt/PCP signalling. EMBO. Rep. 12, 1055-1061 (2011).
13. Parma, P. et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat. Genet 38, 1304-1309 (2006).
14. Kim, K. A. et al. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 309, 1256-1259 (2005).
15. Aoki, M. et al. R-spondin3 is required for mouse placental development. Dev. Biol. 301, 218-226 (2007).
16. Hankenson, K. D., Sweetwyne, M. T., Shitaye, H. & Posey, K. L. Thrombospondins and novel TSR-containing proteins, R-spondins, regulate bone formation and remodeling. Curr. Osteoporos. Rep. 8, 68-76 (2010).
17. Lu, W. et al. R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett. 582, 643-650 (2008).
18. Han, X. H., Jin, Y. R., Seto, M. & Yoon, J. K. A WNT/beta-catenin signaling activator, R-spondin, plays positive regulatory roles during skeletal myogenesis. J. Biol. Chem. 286, 10649-10659 (2011).
19. Theodorou, V. et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat. Genet. 39, 759-769 (2007).
20. Dolmans, G. H. et al. Wnt signaling and Dupuytren's disease. N. Engl. J. Med. 365, 307-317 (2011).
21. Yamada, W. et al. Craniofacial malformation in R-spondin2 knockout mice. Biochem. Biophys. Res. Commun. 381, 453-458 (2009).
22. Bell, S. M. et al. R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis. Development 135, 1049-1058 (2008).
23. Mulvaney, J. F. et al. Secreted factor R-Spondin 2 is involved in refinement of patterning of the mammalian cochlea. Dev. Dyn. 242, 179-18 (2013).
24. Nam, J. S. et al. Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. Dev. Biol. 311, 124-135 (2007).
25. Aoki, M., Kiyonari, H., Nakamura, H. & Okamoto, H. R-spondin2 expression in the apical ectodermal ridge is essential for outgrowth and patterning in mouse limb development. Dev. Growth Differ. 50, 85-95 (2008).
26. Lowther, W., Wiley, K., Smith, G. H. & Callahan, R. A new common integration site, Int7, for the mouse mammary tumour virus in mouse mammary tumours identifies a gene whose product has furin-like and thrombospondin-like sequences. J. Virol. 79, 10093-10096 (2005).
27. Klauzinska, M. et al. Rspo2/Int7 regulates invasiveness and tumorigenic properties of mammary epithelial cells. J. Cell Physiol. 227, 1960-1971 (2012).
28. Starr, T. K. et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323, 1747-1750 (2009).
29. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
30. Kazanskaya, O. et al. R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. Dev. Cell 7, 525-534 (2004).
31. Matsubara, N. Epigenetic regulation and colorectal cancer. Dis. Colon Rectum. 55, 96-104 (2012).
32. Van der Flier, L. G. et al. The Intestinal Wnt/TCF Signature. Gastroenterology 132, 628-632 (2007).
33. Garcia, M. I. et al. LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev. Biol. 331, 58-67 (2009).
34. Walker, F., Zhang, H. H., Odorizzi, A. & Burgess, A. W. LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One 6, e22733 (2011).
35. Hao, H. X. et al. ZNRF3 promotes Wnt receptor turnover in an R-spondinsensitive manner. Nature 485, 195-200 (2012).
36. Uchida, H. et al. Overexpression of leucine-rich repeat-containing G proteincoupled receptor 5 in colorectal cancer. Cancer Sci. 101, 1731-1737 (2010).
37. Suzuki, H. et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 36, 417-422 (2004).
38. Niehrs, C. & Shen, J. Regulation of Lrp6 phosphorylation. Cell Mol. Life Sci. 67, 2551-2562 (2010).
39. Carmon, K. S., Lin, Q., Gong, X., Thomas, A. & Liu, Q. LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/beta-catenin signaling. Mol. Cell Biol. 32, 2054-2064 (2012).
40. Zhou, Y. et al. ZNRF3 acts as a tumour suppressor by the Wnt signalling pathway in human gastric adenocarcinoma. J. Mol. Histol. 44, 555-563 (2013).
41. Chen, P. H., Chen, X., Lin, Z., Fang, D. & He, X. The structural basis of R-spondin recognition by LGR5 and RNF43. Genes Dev. 27, 1345-1350 (2013).
42. Wang, D. et al. Structural basis for R-spondin recognition by LGR4/5/6 receptors. Genes Dev. 27, 1339-1344 (2013).
43. Peng, W. C. et al. Structure of stem cell growth factor R-spondin 1 in complex with the ectodomain of its receptor LGR5. Cell Rep. 3, 1885-1892 (2013).
44. Mustata, R. C. et al. Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo. EMBO. Rep. 12, 558-564 (2011).
45. Hirata-Tominaga, K. et al. Corneal endothelial cell fate is maintained by LGR5 via the regulation of Hedgehog and Wnt pathway. Stem Cells 31, 1396-1407 (2013).
46. Kuang, S. Q. et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukaemia. Leukaemia 22, 1529-1538 (2008).
47. Oka, D. et al. The presence of aberrant DNA methylation in noncancerous oesophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of oesophageal cancers. Cancer 115, 3412-3426 (2009).
48. Davies, R. J., Miller, R. & Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. Nat. Rev. Cancer 5, 199-209 (2005).
49. Petko, Z. et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin. Cancer Res. 11, 1203-1209 (2005).
50. Xue, J. et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology 138, 606-615 (2010).
51. Liao, W. et al. Overexpression of a novel osteopetrosis-related gene CCDC154 suppresses cell proliferation by inducing G2/M arrest. Cell Cycle 11, 3270-3279 (2012).
52. Wang, O. et al. Anticancer activity of 2alpha, 3alpha, 19beta, 23beta-Tetrahydroxyurs-12-en-28-oic acid (THA), a novel triterpenoid isolated from Sinojackia sarcocarpa. PLoS One 6, e21130 (2011).